GSK - Better Buy: Pfizer vs. GlaxoSmithKline
Pharma giants Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) share similar visions for the future. Both aim to transform into smaller, nimbler biopharmaceutical outfits focused on high-value R&D. Last year, investors witnessed the strategy begin to take shape at both businesses.
Image source: Getty Images.
In August 2019, Pfizer and Glaxo completed the combination of their consumer healthcare businesses into a new joint venture. The unit operates under the GSK Consumer Healthcare name, with Glaxo holding a 68% majority stake. The operation boasts the largest global portfolio of over-the-counter medicines, vitamins, minerals, and supplements.